Mm II Assignment

1,196 views

Published on

SANOFI AVENTIS PHARMACEUTICALS

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,196
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
36
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Mm II Assignment

  1. 1. AMARJIT SINGH ID No. MHS1007002<br />
  2. 2. INTRODUCTION<br />Multinational Pharmaceuticals Company.<br />World’s 4th Largest.<br />Founded in 20 August 2004.<br />Head Quarter- Paris, France.<br />
  3. 3. INTRODUCTION<br />CE0 - Chris Viehbacher<br />CHAIRMAN - Jean Francois Dehecq<br />REVENUE - € 29.31 billion (2009)<br />PROFIT - € 5.265 billion (2009)<br />
  4. 4. INTRODUCTION<br />It is a Member of-<br /> European Federation of Pharmaceutical Industries & Associations (EFPIA).<br />
  5. 5. GENERAL INFORMATION<br />Revenue - €29.31billion (2009)<br />Operating Income - €6.366billion (2009)<br />Profit - €5.265billion (2009)<br />Market Share - 4.3%<br />Employees - 104,870 (2009)<br />
  6. 6. WHAT BUSINESS ARE THEY IN<br />Manufacturing & Marketing of Pharmaceutical Products.<br />Over the Counter Medication.<br />Research & Development.<br />
  7. 7. MAJOR THERAPEUTIC AREAS<br />7 major therapeutic areas-<br /><ul><li> Cardiovascular
  8. 8. Central Nervous System
  9. 9. Diabetes
  10. 10. Internal Medicine
  11. 11. Oncology
  12. 12. Thrombosis
  13. 13. Vaccines (World’s largest producer)</li></li></ul><li>POSITIONING OF DIABETES MEDICINE<br />Apidra and Lantus are main products.<br />APIDRA- <br />-Rapid-acting. <br />-Works fast.<br />-Used in children 4 years and <br /> older with type 1 diabetes.<br />-Adults with type 1 or type 2 diabetes.<br />
  14. 14. POSITIONING<br />LANTUS<br />Adult and pediatric patients <br /> with type 1 diabetes mellitus .<br />Adult patients with type 2 <br />diabetesmellitus<br />
  15. 15. TOP PHARMACEUTICAL COMPANIES WITH REVENUES AS PER 2009 ANNUAL REPORT<br />Johnson & Johnson (U.S.) - $ 6,190<br />Pfizer (U.S.) - $ 5,001<br />Roche (Switzerland) - $4,735<br />Glaxo Smith Kline (U.K.) - $4,583<br />Novartis (Switzerland) - $4,427<br />Sanofi Aventis (France) - $4,199 <br />
  16. 16. MARKET SHARE OF DIFFERENT COMPANIES<br />
  17. 17. MAJOR COMPETITORS IN U.S.A.<br />Johnson & Johnson<br />Pfizer<br />Glaxo Smith Kline<br />Bristol-Myers Squibb<br />Astra Zeneca<br />
  18. 18. BRISTOL-MYERS SQUIBB <br />Founded in - 1989<br />Revenue - $18.8 billion(2009)<br />Operating Income - $5.34 billion(2009)<br />Employee’s - 28,000 (2009)<br />
  19. 19. MAIN PRODUCTIONS AREAS INCLUDE<br />Cancer<br />HIV/AIDS <br />Cardiovascular disease <br />Diabetes<br /> Hepatitis <br /> Rheumatoid Arthritis & <br />Psychiatric disorders.<br />
  20. 20. DISTRIBUTION ALL OVER THE WORLD<br />
  21. 21. POSITIONING OF MEDICINE FOR DIABETES <br />ONGLYZA™ (saxagliptin) is the main product for diabetes.<br />Developed and marketed through <br /> a collaboration with AstraZeneca.<br />For the treatment of type 2 diabetes <br /> in adults.<br />
  22. 22. JOHNSON & JOHNSON<br />Founded in - 1886<br />Revenue - $61.9 billion(2009)<br />Operating Income - $15.7 billion(2009)<br />Employee’s - 118,700 (2009)<br />
  23. 23. MAIN PRODUCTIONS AREAS INCLUDE<br />Medical devices<br />Health care products <br />Toiletries <br />Soaps <br />Shampoos <br />
  24. 24. POSITIONING OF MEDICINE FOR DIABETES <br />CANAGLIFLOZIN is the main Product.<br />For Oral Type 2 diabetes. <br />Promote Weight Loss in Treatment <br /> of Type 2 Diabetes.<br />
  25. 25. PFIZER<br />Founded in - 1849<br />Revenue - $50.0 billion(2009)<br />Net Income - $8.63 billion(2009)<br />Employee’s - 116,500 (2009)<br />Ranked No. 2 in sales<br />
  26. 26. MAIN PRODUCTIONS AREAS INCLUDE<br />Lipitor( to lower blood cholesterol)<br />Lyrica(neuropathic drug) <br />Diflucan(the oral antifungal) <br />Antibiotic Zithromax.<br />
  27. 27. POSITIONING OF MEDICINE FOR DIABETES <br />EXUBERA for diabetes and Insulin Therapies<br />Exubera is an Inhaled Insulin <br /> for Type 1 and Type 2 Diabetes<br />Many drugs can interfere with <br />Exubera. <br />
  28. 28. GLAXO SMITH KLINE<br />Founded in - 2000<br />Revenue- £28.36billion(2009)<br />Net Income - £5.66 billion (2009)<br />Employee’s - 99,000 (2009)<br />Ranked No. 1 in sales<br />
  29. 29. MAIN PRODUCTIONS AREAS INCLUDE<br />Asthma <br />Cancer <br />Virus control <br />Mental health <br />Diabetes and <br />Digestive conditions<br />
  30. 30. POSITIONING OF MEDICINE FOR DIABETES <br />AVANDIA is the main product for <br /> diabetes.<br />Oral Drug.<br />To treat Type-2 diabetes.<br />Increase the risk of Heart attack, <br /> Strokes, Fractures, Eye damage.<br />
  31. 31. ASTRA ZENECA<br />Founded in - 2000<br />Revenue -$32,804 million(2009) <br />Net Income - $7,544 million(2009)<br />Employee’s - 116,500 (2009)<br />
  32. 32. MAIN PRODUCTIONS AREAS INCLUDE<br /> Cancer <br /> Cardiovascular <br /> Gastrointestinal infection <br /> Neuroscience <br /> Respiratory disorder <br /> Inflammation.<br />THEY HAVE NO PRODUCT FOR DIABETES.<br />
  33. 33. MAJOR COMPETITORS IN BRAZIL<br />Atlanta Pharmaceuticals.<br />Bayer’s Pharmaceuticals.<br />Novartis Pharmaceuticals.<br />Roche Pharmaceuticals.<br />Ache Laboratories Pharmaceuticals.<br />
  34. 34. BAYER’S PHARMACEUTICALS<br />Founded in - 1863<br />Revenue - €31.17billion(2009)<br />Net Income - €3.0 billion (2009)<br />Employee’s - 108,400 (2009)<br />
  35. 35. MAIN PRODUCTIONS AREAS INCLUDE<br />Veterinary drugs <br />General and specialty medicines <br />Women's health products <br />Over-the-counter drugs <br />Diabetes care <br />
  36. 36. PRODUCT FOR DIABETES<br />Bayer’s Contour USB Meter for<br /> measuring Blood Glucose.<br />Bayer’s Entrust for measuring<br /> Blood Glucose.<br />
  37. 37. NOVARTIS PHARMACEUTICALS<br />Founded in - 1996<br />Revenue - $44.27billion(2009)<br />Net Income - $8.40 billion (2009)<br />Employee’s - 99,830<br />
  38. 38. MAIN PRODUCTIONS AREAS INCLUDE<br />Pharmaceuticals <br />Generic drugs <br />Over-the-counter drugs <br />Vaccines <br />Contact lenses <br />
  39. 39. POSITIONING FOR DIABETES <br />Novartis resource Diabetishield<br />A Nutritional drink formulated for <br /> Individuals with Diabetes. <br />Added arginine, chromium, <br /> and vitamins C and E help to improve insulin <br /> sensitivity and aid in blood sugar control.<br />
  40. 40. ROCHE PHARMACEUTICALS<br />Founded in - 1896<br />Revenue - CHF 49.05billion(2009)<br />Net Income - CHF 12.28 billion (2009)<br />Employee’s - 81,500 (2009)<br />
  41. 41. MAIN PRODUCTIONS AREAS INCLUDE<br />Pharmaceuticals<br />Xenical(Obesity)   <br />Zenapax(Monoclonal Antibody)  <br />Valcyte(Antiviral)  <br />Bactrim (Antibiotic)<br /> Tamiflu (Antiviral)<br />Diagnostics<br />
  42. 42. POSITIONING FOR DIABETES <br />Accu-Chek is the brand of blood sugar -testing device. Include-  <br />Accu-Chek Aviva <br /> Accu-Chek<br /> Compact Plus<br />
  43. 43. ACHE LABORATORIES PHARMACEUTICALS<br />Founded in - 1974<br />The best pharmaceutical lab in Brazil.<br />Employee’s - 3,000<br />
  44. 44. MISSION, VISION AND VALUES<br />VISION-<br /><ul><li>Be the best pharmaceutical lab in Brazil.
  45. 45. Preferred by consumers and health professionals.
  46. 46. Promote the health and well-being of the entire population.</li></li></ul><li>MISSION<br /><ul><li>Continuously make available with quality.
  47. 47. Creativity and convenience.
  48. 48. Innovative and accessible products and services that promote consumer health and well being.
  49. 49. Respect to people and the environment.</li></li></ul><li>VALUES<br /><ul><li>Integrity
  50. 50. Respect to People
  51. 51. Respect to the Environment
  52. 52. Enterprising Spirit
  53. 53. Innovation
  54. 54. Sustainable Growth</li></li></ul><li>COMPETITORS IN GERMANY<br />BoehringerIngelheim<br />Merck KGaA<br />Generics<br />Phytomedicines<br />Bayer Schering Pharma<br />
  55. 55. BOEHRINGER INGELHEIM<br />Founded in - 1885<br />Revenue - €11.595 billion (2008)<br />Net Income - €1.424 billion (2008)<br />Employee’s - 41,300 (2008)<br />
  56. 56. MAIN PRODUCTION AREAS<br /> Human Pharmaceuticals <br /><ul><li>Prescription medicines
  57. 57. Healthcare products</li></ul>Biopharmaceuticals <br />Chemicals<br />Animal health products<br />
  58. 58. POSITIONING FOR DIABETES<br />LINAGLIPTIN is the main product.<br />Effective against Type-II Diabetes.<br />Oral Medicine.<br />Still under trial.<br />
  59. 59. MERCK KGAA<br />Founded in - 1668<br />Revenue - €7.747 billion (2009)<br />Operative Income - €620.9 million (2009)<br />Employee’s - 40,507 (2010)<br />
  60. 60. MAIN PRODUCTION AREAS<br />Liquid crystals<br />Life science and performance <br /> chemicals<br />Over-the-counter medicines<br />Small molecules <br /> Biopharmaceuticals<br />
  61. 61. POSITIONING FOR DIABETES<br />JANUVIA is drug which works <br /> for the management of Type 2 <br /> diabetes.<br />Oral Medicine.<br />Side Effects- severe pain in stomach <br /> nausea and vomiting, loss of appetite, <br /> fast heart rate, fever, sore throat.<br />
  62. 62. BAYER SCHERING PHARMA<br />Founded in - 2006<br />Revenue - €10.267 billion (2007)<br />Employee’s- 26,000 (2004)<br />Headquarter - Germany<br />
  63. 63. MAIN PRODUCTION AREAS<br />Gynaecology & Andrology<br />Special therapeutics Diagnostical<br /> devices<br />Nuclear medicine<br />Oncology<br />
  64. 64. POSITIONING FOR DIABETES<br />Launched SciLin a recombinant insulin product, in China.<br />Oral Drug for Adults.<br />
  65. 65. COMPETITORS IN INDIA<br />Ranbaxy (Daiichi)<br />Dr. Reddy’s Laboratories<br />Cipla<br />Sun Pharma<br />AurobindoPharma<br />
  66. 66. RANBAXY (DAIICHI)<br />Founded in - 1961<br />Revenue - US$ 1,405 million (2010)<br />Net Income - US$ 349 million (2010)<br />Employee’s - 1,100 in R & D<br />Operating in over - 125 Countries<br />Market Share in India - 4.9%<br />
  67. 67. MAIN PRODUCTION AREAS<br />Cardiovascular<br />Central Nervous System<br />Respiratory<br />Dermatology<br />Orthopedics<br />Nutritionals <br />Urology<br />
  68. 68. POSITIONING FOR DIABETES<br />VOLIX (VOGLIBOSE) is the main product for Treatment Of Diabetes.<br />Help in improving of Postprandial Hyperglycemia in Diabetes Mellitus.<br />Oral Drug.<br />Will Launch anti-diabetic drug ACTOS<br /> in the US by 2012. <br />
  69. 69. Dr. REDDY’S LABORATORIES<br />Founded in - 1984<br />Revenue - US$ 1.5 billion (2007)<br />Net Income - US$ 216 million (2007)<br />Employee’s - 8,225<br />Major seller in Europe, Canada and Russian.<br /> Number one in India in terms of profitability.<br />
  70. 70.
  71. 71.
  72. 72. MAIN PRODUCTION AREAS<br />Cancer<br />Diabetes<br />Cardiovascular disease <br />Inflammation<br />Bacterial infection<br />
  73. 73. POSITIONING FOR DIABETES<br />BALAGLITAZONE is the main product for <br /> Diabetes.<br />First lead molecule in <br /> anti-diabetic segment.<br />RAGAGLITAZONE is a new product & is more promising.<br />
  74. 74. CIPLA<br />Founded in - 1935<br />Revenue - US$ 1.28 billion (2010)<br />Net Income - US$ 245.7 million (2010)<br />Employee’s - 7,000<br />2nd Largest Pharmaceutical Company in India in terms of retail sales.<br />
  75. 75. Operating in 170 Countries.<br />
  76. 76. MAIN PRODUCTION AREAS<br />Pharmaceuticals<br />Animal Health Care Products<br />OTC (Over The Counter) Drug<br />Bulk Drugs<br />Flavours& Fragrances<br />Agrochemicals<br />
  77. 77. POSITIONING FOR DIABETES<br />ACARBOSE is main product used for type 2 diabetes mellitus. <br />Oral Medicine.<br />Side Effects- Diarrhea, Hypoglycemia,<br /> Dizziness, Headache.  <br />
  78. 78. SUN PHARMA<br />Founded in - 1983<br />Revenue - Rs 42.7 billion (2009)<br />Net Income - Rs 18.7 billion (2009)<br />Employee’s - 8,000 (2008)<br />
  79. 79. MAIN PRODUCTION AREAS<br />Anticancer<br />Analgesics<br />Antidepressant<br />Antidiabetic<br />Antihypertensive<br />Cardiovascular<br />
  80. 80. POSITIONING FOR DIABETES<br />GLIMEPRIDE & METFORMINE are the main drugs.<br />Used for Type 2 Diabetes.<br />Oral Medicine for Adults.<br />
  81. 81. COMPETITOR’S IN AUSTRALIA<br />Novogen<br />Amrad Corporation<br />Biota Holdings Ltd.<br />Novo Nordisk <br />Pfizer Australia<br />
  82. 82. COMPETITOR’S IN JAPAN<br />Daiichi Sankyo Co. <br />Astellas<br />Chugai Pharma<br />Eisai Co.<br />Takeda Pharma<br />
  83. 83. DAIICHI SANKYO COMPANY <br />Founded in - 2005<br />Revenue - ¥ 880,120 million (2007)<br />Net Income - ¥ 97,660 million (2007)<br />Employee’s - 15,349 (2008)<br />
  84. 84. DIFFERENT PRODUCTS<br />Cravit<br />Evoxac<br />FloxinOtic<br />Gracevit<br />Rivoglitazone—Type 2 Diabetes. It is <br /> still under trial.<br />
  85. 85. EISAI COMPANY<br />Founded in - 1936<br />Revenue - ¥ 781.7 billion (2008)<br />Net Income - ¥ 47.7 billion (2008)<br />Employee’s - 10,962 (2008)<br />
  86. 86. DIFFERENT PRODUCTS<br />Aciphex/Pariet(Gastroesophageal<br /> reflux disease)<br />Actonel (Osteoporosis)<br />Methylcobal(Peripheral <br /> Neuropathy)<br />Myonal (Muscle relaxant)<br />AS-3201 (Diabetic neuropathy)<br />
  87. 87. ASTELLAS PHARMA<br />Founded in - 2005<br />Revenue - ¥ 972.6 billion (2007)<br />Net Income - ¥ 177.4 billion (2007)<br />Employee’s - 13,900 (2007)<br />
  88. 88. DIFFERENT PRODUCTS<br />Prograf (Prevention of post-<br /> transplant organ rejection)<br />Protopic (Atopic dermatitis)<br />AmBisome (Anti-fungal)<br />Mycamine(Anti-fungal)<br />
  89. 89. THANK YOU<br />AMARJIT SINGH<br />

×